Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

3m new zealand ltd - chlorhexidine gluconate 2%{relative};  ; isopropyl alcohol 70%{vol};  ;   - antiseptic solution - active: chlorhexidine gluconate 2%{relative}   isopropyl alcohol 70%{vol}     excipient: purified water - antiseptic for preparation of the patient's skin prior to invasive procedure on dry skin sites only. helps reduce bacteria that potentially can cause skin infection. efficacy on moist sites such as groin has not been demonstrated.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

3m new zealand ltd - chlorhexidine gluconate 2%{relative};  ; isopropyl alcohol 70%{vol};  ;   - antiseptic solution - active: chlorhexidine gluconate 2%{relative}   isopropyl alcohol 70%{vol}     excipient: acid red 33 allura red ac brilliant blue fcf purified water - antiseptic for preparation of the patient's skin prior to invasive procedure on dry skin sites only. helps reduce bacteria that potentially can cause skin infection. efficacy on moist sites such as groin has not been demonstrated.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

3m new zealand ltd - chlorhexidine gluconate 2%{relative} (2.35% overage);  ; isopropyl alcohol 70%{vol};  ;   - antiseptic solution - active: chlorhexidine gluconate 2%{relative} (2.35% overage)   isopropyl alcohol 70%{vol}     excipient: purified water - antiseptic for preparation of the patient's skin prior to invasive procedure on dry skin sites only. helps reduce bacteria that potentially can cause skin infection. efficacy on moist sites such as groin has not been demonstrated.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

apotex nz ltd - cinacalcet hydrochloride 33.06mg equivalent to 30 mg cinacalcet - film coated tablet - 30 mg - active: cinacalcet hydrochloride 33.06mg equivalent to 30 mg cinacalcet excipient: colloidal silicon dioxide croscarmellose sodium fd&c blue no. 1 aluminium lake iron oxide black iron oxide yellow macrogol 8000 magnesium stearate mannitol microcrystalline cellulose polyvinyl alcohol purified talc purified water sodium starch glycolate titanium dioxide - cinacalcet hydrochloride may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as adjunctive therapy.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

apotex nz ltd - cinacalcet hydrochloride 66.12mg equivalent to 60 mg cinacalcet - film coated tablet - 60 mg - active: cinacalcet hydrochloride 66.12mg equivalent to 60 mg cinacalcet excipient: colloidal silicon dioxide croscarmellose sodium fd&c blue no. 1 aluminium lake iron oxide black iron oxide yellow macrogol 8000 magnesium stearate mannitol microcrystalline cellulose polyvinyl alcohol purified talc purified water sodium starch glycolate titanium dioxide - cinacalcet hydrochloride may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as adjunctive therapy.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

apotex nz ltd - cinacalcet hydrochloride 99.18mg equivalent to 90 mg cinacalcet - film coated tablet - 90 mg - active: cinacalcet hydrochloride 99.18mg equivalent to 90 mg cinacalcet excipient: colloidal silicon dioxide croscarmellose sodium fd&c blue no. 1 aluminium lake iron oxide black iron oxide yellow macrogol 8000 magnesium stearate mannitol microcrystalline cellulose polyvinyl alcohol purified talc purified water sodium starch glycolate titanium dioxide - cinacalcet hydrochloride may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. cinacalcet hydrochloride should be used as adjunctive therapy.

Israel - inglês - Ministry of Health

dexcel ltd, israel - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - inglês - Ministry of Health

dexcel ltd, israel - rivaroxaban - film coated tablets - rivaroxaban 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric population: treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment

Israel - inglês - Ministry of Health

dexcel ltd, israel - rivaroxaban - film coated tablets - rivaroxaban 2.5 mg - rivaroxaban - rivaroxaban dexcel 2.5 mg, co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.rivaroxaban dexcel 2.5 mg, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.

Israel - inglês - Ministry of Health

dexcel ltd, israel - rivaroxaban - film coated tablets - rivaroxaban 20 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric population: treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.